$TMO

Thermo Fisher Scientific launched the Orbitrap Isora MS and Orbitrap Isora Pro MS, its first instruments with dedicated isotope ratio analysis mode. The system, paired with the Vanquish Duo UHPLC System and new Isotope Discoverer Software, aims to simplify and speed up isotope ratio analysis for labs studying contaminant sources, metabolic pathways, or food authenticity. The instruments measure isotope ratios directly from intact molecular ions, bypassing gas conversion, and can deliver results

CNBC's 'Final Trades' featured picks from analysts, including Delta Air Lines (DAL) for its strong Q2 earnings, Thermo Fisher Scientific (TMO) for its raised FY2026 guidance, and Target (TGT) for its better-than-expected Q2 results. Interactive Brokers (IBKR) was also mentioned for its new Latin America funding solution. DAL +1.4%, TMO -0.1%, TGT -3.8%, IBKR +5.5%.

Thermo Fisher Scientific launched the Orbitrap Isora Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, its first Orbitrap instruments with dedicated isotope ratio analysis mode. The new workflow integrates mass spectrometry, UHPLC system, and software to make molecular-level isotope ratio analysis more accessible. The instruments offer up to 240K and 480K maximum resolution, respectively, and aim to simplify and speed up analysis for various research fields.

Goldman Sachs identified six stocks, including SpaceX (SPCX), Boeing (BA), Capital One (COF), Mastercard (MA), Thermo Fisher (TMO), and Visa (V), that are overweighted by both hedge funds and mutual funds. These stocks have outperformed the S&P 500 by 29% this year, according to Goldman's analysis. SpaceX trades at 93 times next year's estimated earnings and is a dominant player in reusable rockets and satellite internet.

Thermo Fisher Scientific (TMO) CEO Marc N. Casper filed a Rule 144 notice to sell 275 shares on 08/24/2026 after exercising stock options. He and Floral Park Associates Inc. also sold 10,000 shares each on multiple August 2026 dates, with values ranging from $5.7M to $6.3M. Fidelity Brokerage Services LLC is the broker.

Thermo Fisher Scientific insider sold shares worth $12,561,823, per an SEC filing. The company's stock is currently at $628.74. William O'Neil recently initiated a buy rating on the stock.

Thermo Fisher (TMO) CFO James Meyer had 30.945 shares withheld for tax liability at $629.27 per share on August 22, 2026. He holds 5,830.038 shares directly and 58.37 shares indirectly via a 401(k) plan. The transaction was not a market sale or purchase.

Thermo Fisher (TMO) CEO Marc N. Casper exercised stock options for 20,000 shares at $309.63 each and sold them at $625.46-$633.99, totaling $12.9M. Transactions were under a 10b5-1 plan. Indirect holdings include 16,300 shares in trusts.

CASPER MARC N (Chairman & CEO) sold 20,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $628.09 ($625.45–$633.99, $12.56M total) across 14 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.

Johnson & Johnson (JNJ) reported $16.38B in quarterly sales, raising its annual sales forecast to $101.1B and EPS to $11.68. Thermo Fisher (TMO) showed recovery in life sciences spending, with Life Sciences Solutions revenue up 13%. JNJ's growth is driven by its diversified portfolio, while TMO's depends on industry recovery.